Amsterdam, 21 July 2010 - Under the terms of the agreement Kreatech Diagnostics gets exclusive and worldwide access to the use of Veridex’s Repeat-Free™ technology for the production and distribution of innovative DNA screening solutions (FISH and CISH*) for fast and accurate detection of human genetic diseases in cytogenetics and cancer. The worldwide market exceeds US$ 150 million with an annual growth rate exceeding 10%, whereas the US market is the single largest market for FISH probes. Veridex retains commercialization rights linked to its Circulating Tumor Cell and other rare cell applications.

“The exclusive license is a major step forward for Kreatech as a dedicated player in the field of Molecular Diagnostics. The deal not only offers worldwide freedom to operate in the field of repeat-free FISH and CISH, but also provides Kreatech direct access to the US market and will be utilized to boost Kreatech’s position as a reliable supplier of a broad commercial portfolio of molecular diagnostics used by cytogenetic labs worldwide” says Kees Moonen, CEO of Kreatech Diagnostics.

The US market is the single largest market for FISH probes. FISH assays developed, produced and marketed by Kreatech Diagnostics are tests used by diagnostic and research labs. Having a broad commercial molecular diagnostic product portfolio available today, Kreatech had already focused on growing the business in Europe and will now further expand by entering the US market directly.

The licensed Repeat-Free™ technology eliminates the use of Cot-1 or blocking DNA, providing less background and a brighter signal, important features of FISH as a diagnostic and research tool.

Kreatech aims at boosting its presence in the US market by partnering with experienced players in the field of molecular diagnostics.

Financial details of the license agreement are not disclosed.

About Kreatech Diagnostics
Kreatech Diagnostics, based in Amsterdam, The Netherlands, develops and markets molecular diagnostics worldwide allowing health care providers to make informed decisions about the treatment of patients. Kreatech offers the broadest commercial portfolio available of Fluorescent in Situ Hybridization probes for both diagnostic and research use.

Kreatech’s proprietary labeling technology, the Universal Linkage System (ULS™), allows accurate (non-enzymatic) and fast labeling of DNA, RNA and proteins; one universal system compatible with all biological samples.

Kreatech has the support of leading professional life science investors: US based Alafi Capital and Amsterdam based Life Science Partners are initial investors in Kreatech.

(*) FISH is an abbreviation for Fluorescent In-Situ Hybridization probes and CISH is an abbreviation for Chromogenic In-Situ Hybridization probes.

About Veridex
Veridex, LLC is an organization dedicated to providing physicians with high-value in vitro diagnostic oncology